Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells

Lutz MB, Baur A, Schuler-Thurner B, Schuler G (2014)

Publication Type: Journal article

Publication year: 2014

Journal

OncoImmunology Taylor & Francis

Publisher: Taylor & Francis

Book Volume: 3

Pages Range: e28223

DOI: 10.4161/onci.28223

Abstract

Ontak(®), a conjugate between IL-2 and a diphtheria toxin fragment, was recently investigated in cancer clinical trials aiming to kill CD25(+) regulatory T cells (Tregs). We found that the activity of Ontak(®) was more complex on Tregs and conventional T cells (Tconvs) than anticipated, including a novel strong influence on dendritic cells (DCs).

Authors with CRIS profile

Beatrice Schuler-Thurner Lehrstuhl für Haut- und Geschlechtskrankheiten Gerold Schuler Lehrstuhl für Haut- und Geschlechtskrankheiten

Involved external institutions

Julius-Maximilians-Universität Würzburg DE Germany (DE)

How to cite

APA:

Lutz, M.B., Baur, A., Schuler-Thurner, B., & Schuler, G. (2014). Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells. OncoImmunology, 3, e28223. https://doi.org/10.4161/onci.28223

MLA:

Lutz, Manfred B., et al. "Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells." OncoImmunology 3 (2014): e28223.

BibTeX: Download